Inflammatory bowel disease
Results of a Phase IIb trial of the company’s anti-TL1A antibody showed more than a third of ulcerative colitis patients entered remission while receiving the experimental treatment.
Eli Lilly stands to gain access to DICE Therapeutics’ DELSCAPE platform, which enables the design of orally available molecules for autoimmune and inflammatory diseases.
Pfizer and Eli Lilly are forging ahead with ulcerative colitis (UC) research after posting positive results from their respective Phase III studies.
The San Diego-based immunology company is locating and developing molecules where the mechanism of action has either been proven or makes sense.
In the deal, Boehringer acquired worldwide exclusive rights to Enleofen’s preclinical interleukein-11 (IL-11) platform.
The FDA approved extended-release 11 mg and 22 mg tablets as a once-daily treatment from the chronic inflammatory condition.
A peculiarity of autoimmune diseases is that they have many genes in common, but they develop differently.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
The drug showed what the company is calling a “substantial improvement in this symptom-driven score” at the 12-week point, but it did not differentiate from placebo.
PRESS RELEASES